Ensysce Biosciences (ENSCW) Free Cash Flow (2018 - 2025)

Ensysce Biosciences (ENSCW) has 8 years of Free Cash Flow data on file, last reported at -$1.9 million in Q3 2025.

• Free Cash Flow for Q3 2025 came in at -$1.9 million, down 82.9% year-over-year; the trailing twelve-month figure through Dec 2025 was -$6.3 million (up 16.29% YoY), and the FY2024 annual result was -$7.5 million, up 30.4% from the prior year.
• Free Cash Flow improved to -$1.9 million in Q3 2025 per ENSCW's latest filing, from -$2.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$132312.0 in Q2 2021 and troughed at -$6.7 million in Q3 2022.
• A 5-year average of -$2.7 million and a median of -$2.7 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow tumbled 3256.08% in 2022, then soared 66.3% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$3.8 million in 2021, then rose by 12.53% to -$3.3 million in 2022, then jumped by 45.33% to -$1.8 million in 2023, then surged by 57.59% to -$764090.0 in 2024, then plunged by 144.24% to -$1.9 million in 2025.
• Business Quant data shows ENSCW's Free Cash Flow at -$1.9 million in Q3 2025, -$2.7 million in Q2 2025, and -$1.7 million in Q1 2025.